Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page / H9 H5 p |: @" _9 m3 g" C
* N9 |* k7 E) n/ A
- Y) V$ a9 {6 j$ t5 s* |+ P4 N% YSub-category:" \# z) M! p; ^" D
Molecular Targets
: s: t: a: T4 q# ]
* n. E+ L( U3 y6 f+ c/ ?* X5 X
( L/ n, r2 p! M) Q) aCategory:1 n6 I2 d' G. r" N& e P
Tumor Biology " _* z; G+ z1 i& e2 P4 `
( c: z- I) Y/ y' f- \3 `6 ]
6 n2 d$ G8 F! y' l
Meeting:9 B4 e x) t. T9 Q. W: { \: ~
2011 ASCO Annual Meeting
2 x$ i# q! H- J# s! r1 H7 h1 Z' k# q4 q7 E) K6 q
, g }: H: e2 P* C
Session Type and Session Title:
5 N$ L. T" l: Q$ O UPoster Discussion Session, Tumor Biology ; T5 J& \ k. O) p
6 V5 \# ]' H* m& m( t
& A l I6 i6 r& E3 FAbstract No:
5 i: x2 D) D" _) E+ R! {10517
% d4 @: i i! {. V( [' q6 I" f
. X3 O7 m3 ^ I u
% X3 f3 D# D0 r% H+ w6 H* u* j- kCitation:
$ @9 f' }( b4 g% V. a+ y# pJ Clin Oncol 29: 2011 (suppl; abstr 10517) $ A* S- O+ ^0 Z- M
1 @# n' }- @; x# V& i
( L0 @9 g+ W) y- c( ]. }! d
Author(s):: ?- \$ ]# Q0 R$ w; {( s
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China ; g+ I% w+ h, i: y6 y
, N) `3 e: [ ~% s& f+ p
8 \1 m% o, n) d7 { r [
7 v. r/ M. k6 l. y- Y/ E! M/ D- LAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.' z s! s3 t2 D& J
; Y7 f0 r( T3 ^3 E8 Z
Abstract Disclosures
! A4 \/ Q( b7 M9 p; W9 |" S8 `5 A. F4 I
Abstract:
1 I; \9 K8 d% y+ M$ n0 p: n% x% k
4 Y1 f' e: q" u+ m1 r+ C0 W- t8 V6 R6 L1 a( M- R" O
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
9 F+ s8 k& @* T0 \/ r4 B; |
3 [, C8 `* C1 B+ \4 b1 W @/ A( f' J1 h: X: A$ f+ n; v2 J. m
|
3 V/ Y( |: h$ B+ q4 J- P& }# F9 m
显身卡
